Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about Low Dose Naltrexone (LDN) as a repurposed cancer treatment option in this 15-minute educational video featuring Professor of Oncology Angus Dalgleish. Discover how naltrexone, originally designed to block opioid receptors for addiction treatment, shows promising potential in cancer therapy when administered at very low doses. Explore three key mechanisms through which LDN may influence cancer progression: antagonism of toll-like receptors leading to IL-6 suppression, modulation of immune function, and direct inhibition of cancer cell signaling pathways including pro-apoptotic pathway priming. Examine the growing body of anecdotal evidence supporting LDN's effectiveness in cancer resolution and understand why this is driving increased interest in clinical trials, particularly when LDN is combined with certain chemotherapy treatments. Access comprehensive research references and resources from the LDN Research Trust to deepen your understanding of this emerging therapeutic approach in oncology.
